Giant-Cell Arteritis Global Market Report 2025

Description

Giant-cell arteritis (GCA) is a form of vasculitis, characterized by inflammation of medium to large arteries. It often affects the temporal arteries, causing symptoms such as headaches, scalp tenderness, and vision issues. If untreated, GCA can lead to severe complications such as blindness or stroke due to inflammation of vessel walls. Treatment typically involves high doses of corticosteroids to reduce inflammation and prevent complications.

Common therapeutics for giant-cell arteritis include prednisone, methotrexate, tocilizumab, and aspirin. Prednisone, a corticosteroid, works by suppressing inflammation and immune responses. It is administered via various routes such as oral, intravenous, and subcutaneous, and is utilized for its anti-inflammatory, immunosuppressive, and anticoagulant properties.

The giant-cell arteritis market research report is one of a series of new reports from The Business Research Company that provides giant-cell arteritis market statistics, including giant-cell arteritis industry global market size, regional shares, competitors with a giant-cell arteritis market share, detailed giant-cell arteritis market segments, market trends and opportunities, and any further data you may need to thrive in the giant-cell arteritis industry. This giant-cell arteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The giant-cell arteritis market size has grown strongly in recent years. It will grow from $1.07 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to epidemiological studies, genetic insights, increasing adoption of biologics, improving diagnostic techniques, and development of targeted therapies and biologics.

The giant-cell arteritis market size is expected to see steady growth in the next few years. It will grow to $1.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to increasing diagnosis rates, aging population, rising healthcare expenditure, patient advocacy, expansion into new geographic regions. Major trends in the forecast period include advancements in identifying and validating biomarkers, development of therapies targeting specific molecular pathways, adoption of advanced imaging techniques, drug delivery innovations, utilization of AI algorithms for predictive analytics.

The increasing focus on personalized medicine is expected to drive growth in the giant-cell arteritis market in the coming years. Personalized medicine involves tailoring medical treatments to individual characteristics such as genetics, lifestyle, and environmental factors. This approach is gaining momentum due to advancements in genomics, biotechnology, and data analytics, which enable more precise therapies that enhance treatment effectiveness and minimize side effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can lead to targeted therapies based on factors such as genetic predispositions, immune responses, and specific disease symptoms. For example, according to the Personalized Medicine Coalition (PMC) in February 2024, over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) in 2023 were for personalized medicines. This marked the fourth consecutive year of significant growth, with 16 new treatments tailored for rare diseases approved, compared to six approvals in 2022. These approvals included medications for cancer and other conditions, underscoring the increasing adoption of personalized approaches in healthcare and their impact on disease management such as GCA.

Leading companies in the giant-cell arteritis market are advancing by introducing new products such as biosimilars to expand treatment options and meet patient needs. Biosimilars are biologic drugs highly similar to approved biological products, ensuring no clinically meaningful differences in safety, purity, and potency. For instance, in April 2024, Fresenius SE & Co. KGaA launched Tocilizumab-aazg in the U.S., a biosimilar approved for chronic autoimmune diseases including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval followed a comprehensive evaluation in a phase 1 trial comparing its pharmacokinetics, safety, and immunogenicity to reference tocilizumab products.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired Teva's manufacturing facility in Goa, India, enhancing its production capacity significantly. This acquisition doubles Marksans Pharma's manufacturing capabilities in India, enabling the production of various pharmaceutical products including tablets, capsules, ointments, liquids, and creams. Teva Pharmaceutical, based in Israel, is known for its contributions in producing medications such as prednisone tablets used in the treatment of giant-cell arteritis.

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the giant-cell arteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The giant-cell arteritis market consists of revenues earned by entities by services such as monitoring and follow-up, supportive care, diagnostic testing, treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The giant-cell arteritis market also includes sales of biologics, diagnostic tools, biopsy kits and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Giant-Cell Arteritis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on giant-cell arteritis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for giant-cell arteritis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The giant-cell arteritis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin
2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action
3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration
Subsegments:
1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy
2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy
3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids
4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r30319

1. Executive Summary

2. Giant-Cell Arteritis Market Characteristics

3. Giant-Cell Arteritis Market Trends And Strategies

4. Giant-Cell Arteritis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Giant-Cell Arteritis Growth Analysis And Strategic Analysis Framework

5.1. Global Giant-Cell Arteritis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Giant-Cell Arteritis Market Growth Rate Analysis
5.4. Global Giant-Cell Arteritis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Giant-Cell Arteritis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Giant-Cell Arteritis Total Addressable Market (TAM)

6. Giant-Cell Arteritis Market Segmentation

6.1. Global Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisone
Methotrexate
Tocilizumab
Aspirin
6.2. Global Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Other Mechanisms Of Action
6.3. Global Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Subcutaneous
Other Routes Of Administration
6.4. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Prednisone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Prednisone
Intravenous (IV) Prednisone
Low-Dose Prednisone Therapy
High-Dose Prednisone Therapy
6.5. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Methotrexate, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Methotrexate
Subcutaneous Methotrexate
Methotrexate Monotherapy
Methotrexate Combination Therapy
6.6. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Tocilizumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous Tocilizumab
Subcutaneous Tocilizumab
Tocilizumab Monotherapy
Tocilizumab In Combination With Corticosteroids
6.7. Global Giant-Cell Arteritis Market, Sub-Segmentation Of Aspirin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Low-Dose Aspirin Therapy
Aspirin For Cardiovascular Risk Management
Aspirin In Combination Therapy
Enteric-Coated Aspirin

7. Giant-Cell Arteritis Market Regional And Country Analysis

7.1. Global Giant-Cell Arteritis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Giant-Cell Arteritis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Giant-Cell Arteritis Market

8.1. Asia-Pacific Giant-Cell Arteritis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Giant-Cell Arteritis Market

9.1. China Giant-Cell Arteritis Market Overview
9.2. China Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Giant-Cell Arteritis Market

10.1. India Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Giant-Cell Arteritis Market

11.1. Japan Giant-Cell Arteritis Market Overview
11.2. Japan Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Giant-Cell Arteritis Market

12.1. Australia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Giant-Cell Arteritis Market

13.1. Indonesia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Giant-Cell Arteritis Market

14.1. South Korea Giant-Cell Arteritis Market Overview
14.2. South Korea Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Giant-Cell Arteritis Market

15.1. Western Europe Giant-Cell Arteritis Market Overview
15.2. Western Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Giant-Cell Arteritis Market

16.1. UK Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Giant-Cell Arteritis Market

17.1. Germany Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Giant-Cell Arteritis Market

18.1. France Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Giant-Cell Arteritis Market

19.1. Italy Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Giant-Cell Arteritis Market

20.1. Spain Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Giant-Cell Arteritis Market

21.1. Eastern Europe Giant-Cell Arteritis Market Overview
21.2. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Giant-Cell Arteritis Market

22.1. Russia Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Giant-Cell Arteritis Market

23.1. North America Giant-Cell Arteritis Market Overview
23.2. North America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Giant-Cell Arteritis Market

24.1. USA Giant-Cell Arteritis Market Overview
24.2. USA Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Giant-Cell Arteritis Market

25.1. Canada Giant-Cell Arteritis Market Overview
25.2. Canada Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Giant-Cell Arteritis Market

26.1. South America Giant-Cell Arteritis Market Overview
26.2. South America Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Giant-Cell Arteritis Market

27.1. Brazil Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Giant-Cell Arteritis Market

28.1. Middle East Giant-Cell Arteritis Market Overview
28.2. Middle East Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Giant-Cell Arteritis Market

29.1. Africa Giant-Cell Arteritis Market Overview
29.2. Africa Giant-Cell Arteritis Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Giant-Cell Arteritis Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Giant-Cell Arteritis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Giant-Cell Arteritis Market Competitive Landscape And Company Profiles

30.1. Giant-Cell Arteritis Market Competitive Landscape
30.2. Giant-Cell Arteritis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Giant-Cell Arteritis Market Other Major And Innovative Companies

31.1. Bayer AG
31.2. Sanofi SA
31.3. Bristol-Myers Squibb Company
31.4. Novartis AG
31.5. GlaxoSmithKline Plc
31.6. Takeda Pharmaceutical Company Limited
31.7. Eli Lilly and Company
31.8. Amgen Inc.
31.9. Boehringer Ingelheim
31.10. Teva Pharmaceutical Industries Ltd.
31.11. Regeneron Pharmaceuticals Inc.
31.12. Astellas Pharma Inc.
31.13. CSL Limited
31.14. Kiniksa Pharmaceuticals Ltd.
31.15. MorphoSys AG

32. Global Giant-Cell Arteritis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Giant-Cell Arteritis Market

34. Recent Developments In The Giant-Cell Arteritis Market

35. Giant-Cell Arteritis Market High Potential Countries, Segments and Strategies

35.1 Giant-Cell Arteritis Market In 2029 - Countries Offering Most New Opportunities
35.2 Giant-Cell Arteritis Market In 2029 - Segments Offering Most New Opportunities
35.3 Giant-Cell Arteritis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer